+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cervical Cancer Diagnostics Global Market Report 2020-30: COVID-19 Growth and Change

  • ID: 5181441
  • Report
  • October 2020
  • Region: Global
  • 200 pages
  • The Business Research Company
UP TO OFF
until Dec 31st 2020
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Abbott Laboratories
  • Becton, Dickinson and Co.
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • Guided Therapeutics
  • Hologic Inc.
  • MORE
Cervical Cancer Diagnostics Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global cervical cancer diagnostics market.

This report focuses on cervical cancer diagnostics market which is experiencing strong growth. The report gives a guide to the cervical cancer diagnostics market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pand emic.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:

Where is the largest and fastest growing market for the cervical cancer diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Cervical Cancer Diagnostics market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive land scape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider cervical cancer diagnostics market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive land scape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The cervical cancer diagnostics market section of the report gives context. It compares the cervical cancer diagnostics market with other segments of the cervical cancer diagnostics market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, cervical cancer diagnostics indicators comparison.
Scope

Markets Covered:
1) By Diagnostic Test: Pap Smear Test; HPV Test; Colposcopy; Biopsy and Endocervical Curettage; Other Diagnostic Tests
2) By End User: Hospitals; Specialty Clinics; Cancer and Radiation Therapy Centres; Diagnostic Centres

Companies Mentioned: Abbott Laboratories; Becton, Dickinson and Co.; Bio-Rad Laboratories Inc.; F. Hoffmann-La Roche Ltd.; Hologic Inc.

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Becton, Dickinson and Co.
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • Guided Therapeutics
  • Hologic Inc.
  • MORE
1. Executive Summary

2. Cervical Cancer Diagnostics Market Characteristics

3. Cervical Cancer Diagnostics Market Size And Growth
3.1. Global Cervical Cancer Diagnostics Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Cervical Cancer Diagnostics Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Cervical Cancer Diagnostics Market Segmentation
4.1. Global Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Pap Smear Test
  • HPV Test
  • Colposcopy
  • Biopsy and Endocervical Curettage
  • Other Diagnostic Tests
4.2. Global Cervical Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Cancer and Radiation Therapy Centres
  • Diagnostic Centres
5. Cervical Cancer Diagnostics Market Regional And Country Analysis
5.1. Global Cervical Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Cervical Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

6. Asia-Pacific Cervical Cancer Diagnostics Market
6.1. Asia-Pacific Cervical Cancer Diagnostics Market Overview
6.2. Asia-Pacific Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

7. China Cervical Cancer Diagnostics Market
7.1. China Cervical Cancer Diagnostics Market Overview
7.2. China Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

8. India Cervical Cancer Diagnostics Market
8.1. India Cervical Cancer Diagnostics Market Overview
8.2. India Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

9. Japan Cervical Cancer Diagnostics Market
9.1. Japan Cervical Cancer Diagnostics Market Overview
9.2. Japan Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

10. Australia Cervical Cancer Diagnostics Market
10.1. Australia Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

11. Indonesia Cervical Cancer Diagnostics Market
11.1. Indonesia Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

12. South Korea Cervical Cancer Diagnostics Market
12.1. South Korea Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

13. Western Europe Cervical Cancer Diagnostics Market
13.1. Western Europe Cervical Cancer Diagnostics Market Overview
13.2. Western Europe Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

14. UK Cervical Cancer Diagnostics Market
14.1. UK Cervical Cancer Diagnostics Market Overview
14.2. UK Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

15. Germany Cervical Cancer Diagnostics Market
15.1. Germany Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

16. France Cervical Cancer Diagnostics Market
16.3. France Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

17. Eastern Europe Cervical Cancer Diagnostics Market
17.1. Eastern Europe Cervical Cancer Diagnostics Market Overview
17.2. Eastern Europe Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

18. Russia Cervical Cancer Diagnostics Market
18.1. Russia Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

19. North America Cervical Cancer Diagnostics Market
19.1. North America Cervical Cancer Diagnostics Market Overview
19.2. North America Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

20. USA Cervical Cancer Diagnostics Market
20.1. USA Cervical Cancer Diagnostics Market Overview
20.2. USA Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

21. South America Cervical Cancer Diagnostics Market
21.1. South America Cervical Cancer Diagnostics Market Overview
21.2. South America Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

22. Brazil Cervical Cancer Diagnostics Market
22.1. Brazil Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

23. Middle East Cervical Cancer Diagnostics Market
23.1. Middle East Cervical Cancer Diagnostics Market Overview
23.2. Middle East Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

24. Africa Cervical Cancer Diagnostics Market
24.1. Africa Cervical Cancer Diagnostics Market Overview
24.2. Africa Cervical Cancer Diagnostics Market, Segmentation By Diagnostic Test, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

25. Cervical Cancer Diagnostics Market Competitive Landscape And Company Profiles
25.1. Cervical Cancer Diagnostics Market Competitive Landscape
25.2. Cervical Cancer Diagnostics Market Company Profiles
25.2.1. Abbott Laboratories
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. Becton, Dickinson and Co.
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Bio-Rad Laboratories Inc.
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. F. Hoffmann-La Roche Ltd.
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. Hologic Inc.
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Cervical Cancer Diagnostics Market

27. Cervical Cancer Diagnostics Market Trends And Strategies

28. Cervical Cancer Diagnostics Market Future Outlook and Potential Analysis

29. Appendix
29.1. Abbreviations
29.2. Currencies
29.3. Research Inquiries
29.4. About the Publisher
29.5. Copyright And Disclaimer
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Abbott Laboratories
  • Becton, Dickinson and Co.
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • Guided Therapeutics
  • Hologic Inc.
  • MORE
Major players in the cervical cancer diagnostics market are Abbott Laboratories, Becton, Dickinson and Co., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Hologic Inc., QIAGEN NV, Quest Diagnostics Inc., Siemens Healthineers AG, Zilico, and Guided Therapeutics.

The global cervical cancer diagnostics market is expected to decline from $8.02 billion in 2019 to $7.23 billion in 2020 at a compound annual growth rate (CAGR) of -9.87%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, especially postponement of non-emergency procedures. The market is then expected to recover and reach $8.62 billion in 2023 at a CAGR of 6.04%.

The cervical cancer diagnostics market consists of sales of cervical cancer diagnostic devices and related services by entities (organizations, sole traders and partnerships) that produce cervical cancer diagnostics devices. Cervical cancer is a type of cancer that occurs in cells of the cervix. These devices are used for the diagnosis of cervical cancer.

North America was the largest region in the cervical cancer diagnostics market in 2019.

In November 2018, QIAGEN, a German-based leading supplier of specimen and assay systems for diagnostic techniques, applied testing, academic and pharmaceutical research, collaborated with Self-screen BV and released the QIAscreen HPV PCR Test, a CE-IVD molecular diagnostic test for the detection of 15 recognized high-risk human papillomavirus (HPV) genotypes, which is considered to be the cause of cervical cancer. Self-screen BV is a VU University Medical Centre’s spinoff company based in the Netherlands.

The rising adoption of cervical cancer diagnostic tests for the early detection of cervical cancer is expected to drive the market for cervical cancer diagnostics. Increasing awareness among women about cervical cancer along with the emphasis by worldwide cancer organizations and governments on early testing for detecting cervical cancer and preventing it contributes to the growth of the market. For instance, in August 2018, the United States Preventive Services Task Force has updated its screening guidelines for cervical cancer, which specifies that women between ages 21 to 29 should be screened with a Pap test every 3 years, women between ages 30 to 65 should be screened with any of three tests, namely high-risk HPV testing alone, Pap and high-risk HPV contesting for every 5 years and Pap test alone for every 3 years. The rising adoption of cervical cancer diagnostic tests and emphasis on early diagnosis propels the market.

The increased adoption of HPV home testing kits is expected to be the new trend in the market. The home-based HPV testing kits help women in collecting samples and getting the results conveniently on their own without going to the lab for screening. Therefore, companies are focusing on providing convenience to patients. For instance, in January 2019, Nurx, a consumer health and telemedicine company, introduced lab testing that allows women to easily and affordably monitor their risk of cervical cancer from the comfort of their home. Similarly, in April 2019, Matter introduced three conceptual cervical cancer examinations through the Sukha project that help women carry out tests at home to break the stigma associated with cervical testing.

The increased use of HPV vaccination is anticipated to hinder the cervical cancer diagnostics market. According to the World Health Organization, the 2 HPV types (16 and 18) cause 70% of cervical cancers and pre-cancerous cervical lesions, thereby giving human papillomavirus (HPV) vaccine is effectively reducing the numbers of cervical pre-cancerous lesions that may develop into cervical cancers. The study published in Cancer Epidemiology, Biomarkers & Prevention, in February 2019 supported the information from the Centers for Disease Control and Prevention (CDC) that states that among women who had been vaccinated, the share of precancers caused by HPV 16 and 18 dropped from 55.2% to 33.3% whereas, in unvaccinated women, the proportion dropped from 51% to 47.3%. The HPV vaccine is recommended by the Centers for Disease Control and Prevention (CDC) for all the kids and adults between the ages of 9 to 26. Therefore, the increased use of HPV vaccination is predicted to hinder the cervical cancer diagnostics market.
Note: Product cover images may vary from those shown
4 of 5
  • Abbott Laboratories
  • Becton, Dickinson and Co.
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.
  • Hologic Inc.
  • QIAGEN NV
  • Quest Diagnostics Inc.
  • Siemens Healthineers AG
  • Zilico
  • Guided Therapeutics
Note: Product cover images may vary from those shown
5 of 5

Loading
LOADING...

Adroll
adroll